Expanding capabilities and capacity in formulation development and safety assessment
GREENWICH, CT, Oct. 13, 2016 /CNW/ - Aptuit, LLC today announced that it has relocated its recently acquired subsidiary Kuecept to its Oxford UK site, and added further formulation and safety assessment capacity to meet sustained customer demand for IND de-risking and enabling packages.
(Logo: http://photos.prnewswire.com/prnh/20150709/234432LOGO )
Kuecept, now part of the Aptuit group, provides phase appropriate pre-formulation testing, preclinical dose-vehicle screening and formulation development. Kuecept has specialist expertise in respiratory, parenteral and oral formulation development. It also offers formulation rescue consultancy supporting companies moving challenging APIs through IND/CTA enabling safety assessment.
Aptuit CEO Dr. Jonathan Goldman stated, "We have invested over $2.5m in the last 6 months in our formulation development services both in Verona and Oxford. This continued investment allows us to offer seamless integrated solutions in Drug Discovery, CMC and Preclinical Biosciences. The new laboratories, equipment and people have significantly increased our capacity and expertise in this early development space. We have also focused on improving our ability to handle high potency compounds. This continued expansion allows us to further improve the transition of drug candidates from the discovery medicinal chemistry space through to formal regulatory based Drug Product Development. I believe the market demand for our unique fully integrated candidate to IND/CTA solutions (INDiGO®) will continue. We expect our customers to benefit from improved solubility solutions, reduced drug attrition and significant reductions in time and development costs."
Dr. Mark Saunders, CEO and Founder of Kuecept added, "The relocation into our new labs in Oxford has enabled us to continue our aggressive expansion plans to meet the growing customer need for early formulation development solutions. The integration into Aptuit group is already opening up significant new business both for standalone work and integrated development solutions. The integration has shown Kuecept and Aptuit share a common culture and commitment to scientific excellence."
Aptuit, LLC provides the most complete set of integrated early discovery to mid-phase drug development services in the pharmaceutical industry including Drug Design & Discovery, API Development and Manufacture, Solid State Chemistry, CMC, Preclinical and IND enabling GLP/GMP programs. Fully integrated drug discovery & development services are available from our facilities in the UK, Italy, and Switzerland. Aptuit, LLC is partnered with Welsh, Carson, and Anderson & Stowe, one of the world's leading private equity investors.
For more information, please visit http://www.aptuit.com
SOURCE Aptuit, LLC